Excess Serum Interleukin-18 Distinguishes Patients with Pathogenic Mutations in PSTPIP1 - Stone, Deborah L.; Ombrello, Amanda; Arostegui, Juan I.; Schneider, Corinne; Jesus, Adriana de; Girard-Guyonvarc’h, Charlotte; Gabay, Cem; Lee, Wonyong; Chae, Jae Jin; Aksentijevich, Ivona; Goldbach-Mansky, Raphaela; Kastner, Daniel L.; et al. (medRxiv, 2021)
Objective Dominantly-inherited mutations in PSTPIP1 cause a family of monogenic autoinflammatory diseases epitomized by Pyogenic Arthritis, Pyoderma gangrenosum, and Acne (PAPA) syndrome. The connections between PSTPIP1 and PAPA are poorly understood, although in vitro evidence suggests increased activation of the pyrin-inflammasome. We sought to identify biomarkers of potential mechanistic, diagnostic, and therapeutic utility specific to autoinflammatory diseases.Methods Clinical and genetic data and sera were obtained from patients referred with concern for PAPA syndrome, as well as relevant disease controls. Serum Interleukin-18 (IL-18) and related biomarkers were assessed by bead-based assay.Results Symptoms in PSTPIP1 mutation-positive PAPA patients overlapped with those of mutation-negative PAPA-like patients, but the former were younger at onset and had more arthritis. We found uniform elevation of total IL-18 in PAPA patients at a level approaching NLRC4-associated Macrophage Activation Syndrome (MAS) and well beyond Familial Mediterranean Fever. IL-18 elevation in PAPA patients’ sera persisted despite fluctuations in disease activity. IL-18 Binding Protein (IL-18BP) was modestly elevated, and as such PAPA patients had detectable free IL-18. PAPA patients did not develop MAS, and CXCL9 (an indicator of Interferon-gamma activity) was rarely elevated in their sera.Conclusion PAPA syndrome is a refractory, and often disabling monogenic autoinflammatory disease associated with chronic elevation of serum IL-18, but not risk for MAS. This finding instructs our understanding of the origins of excess IL-18, its potential spectrum of pathogenic effects, and the possible role for IL-18 blockade in refractory PAPA syndrome.Competing Interest StatementCG and SC report research support, unrelated to this proposal, from AB2Bio, Ltd. RGM reports research support from Lilly.Funding StatementFinancial Support: Intramural Research Programs of the National Human Genome Research Institute and National Institute of Allergy and Infectious Disease (NIAID), the University Hospital of Geneva, The Institut d'Investigacions Biomediques August Pi i Sunyer, The RK Mellon Insitute for Pediatric Research, and extramural funding from NIAID and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients were recruited to, consented to, and evaluated as part of Natural History protocols approved by the Institutional Review Boards of 1) the intramural research program (IRP) of the National Human Genome Research Institute, 2) the IRP of the National Institute of Allergy and Infectious Diseases, 3) the University of Pittsburgh, and 4) the Hospital Clinic/Institut d'Investigacions Biomediques, Barcelona.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesn/a